Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Peripheral Arterial Disease: Features

Dr Beasley
AMP 2023
The HEAL Registry: Outcomes at 6 Months Post MicroStent Implantation
11/09/2023
Dr. Robert Beasley, vascular specialist from Palm Vascular Centers in Miami Beach, Florida, reviews outcomes from the HEAL Registry for patients with CLI 6 months after implantation of the MicroStent system.
Dr. Robert Beasley, vascular specialist from Palm Vascular Centers in Miami Beach, Florida, reviews outcomes from the HEAL Registry for patients with CLI 6 months after implantation of the MicroStent system.
Dr. Robert Beasley, vascular...
11/09/2023
Vascular Disease Management
Dr Craig Walker
AMP 2023
The Value of Debulking and Vessel Prep Before Drug Delivery
11/09/2023
Dr. Craig Walker, from the Cardiovascular Institute of the South in Houma, Louisiana, discusses his presentation on using vessel prep before drug-coated balloon delivery.
Dr. Craig Walker, from the Cardiovascular Institute of the South in Houma, Louisiana, discusses his presentation on using vessel prep before drug-coated balloon delivery.
Dr. Craig Walker, from the...
11/09/2023
Vascular Disease Management
Video
Reviewing the Guidelines and Clinical Data on Atherectomy and Plaque Modification
10/31/2023
In light of recent reports alleging overuse of atherectomy devices, Matthew Finn, MD, revisits the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports alleging overuse of atherectomy devices, Matthew Finn, MD, revisits the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports...
10/31/2023
Vascular Disease Management
Editor's Corner
Atherectomy in the Infrainguinal Arteries
10/30/2023
In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports...
10/30/2023
Vascular Disease Management
Interview
Overcoming Barriers to Implementation of VOYAGER Results Into Everyday Practice
10/30/2023
Dr. Rogers provides insight into the barriers that may be preventing clinicians from implementing VOYAGER-PAD findings into everyday practice.
Dr. Rogers provides insight into the barriers that may be preventing clinicians from implementing VOYAGER-PAD findings into everyday practice.
Dr. Rogers provides insight into...
10/30/2023
Vascular Disease Management
Dr Ramon Varcoe
AMP 2023
FDA Determination: Data Does Not Support an Excess Mortality Risk for Paclitaxel-Coated Devices
10/24/2023
In this video recorded at AMP 2023, vascular surgeon Dr. Ramon Varcoe talks about his presentation on the new FDA determination that paclitaxel-coated devices are safe for use.
In this video recorded at AMP 2023, vascular surgeon Dr. Ramon Varcoe talks about his presentation on the new FDA determination that paclitaxel-coated devices are safe for use.
In this video recorded at AMP...
10/24/2023
Vascular Disease Management
Dr Brodmann
AMP 2023
One-Year Results of the DEEPER LIMUS Trial
10/16/2023
Marianne Brodmann, MD, discusses her AMP 2023 presentation on the latest results of the DEEPER LIMUS trial,
Marianne Brodmann, MD, discusses her AMP 2023 presentation on the latest results of the DEEPER LIMUS trial,
Marianne Brodmann, MD, discusses...
10/16/2023
Vascular Disease Management
Dr N'Dandu
AMP 2023
Latest Results of the PROMISE II US Pivotal Trial of the LimFlow System
10/04/2023
In this video recorded at AMP 2023, interventional cardiologist Zola N'Dandu, MD, discusses his presentation on the latest results of the PROMISE II U.S. Pivotal Trial, which investigated the safety and effectiveness of the LimFlow System.
In this video recorded at AMP 2023, interventional cardiologist Zola N'Dandu, MD, discusses his presentation on the latest results of the PROMISE II U.S. Pivotal Trial, which investigated the safety and effectiveness of the LimFlow System.
In this video recorded at AMP...
10/04/2023
Vascular Disease Management
Drs Nair and Yost
Podcast
New Data on Peripheral Arterial Disease Prevalence in the United States
10/02/2023
In this episode, interventional cardiologist Dr. Pradeep Nair speaks with Mary Yost, MBA, president of The Sage Group, about her newly published research on the current prevalence of peripheral arterial disease (PAD) in the United States.
In this episode, interventional cardiologist Dr. Pradeep Nair speaks with Mary Yost, MBA, president of The Sage Group, about her newly published research on the current prevalence of peripheral arterial disease (PAD) in the United States.
In this episode, interventional...
10/02/2023
Vascular Disease Management
Interview
Why Are We Failing to Prevent Amputations?
09/21/2023
At the 2023 Amputation Prevention Symposium (AMP), Mary Yost, MBA, president of the Sage Group, the leading research and consulting company specializing in peripheral vascular disease, presented her thoughts on the reasons why clinicians are...
At the 2023 Amputation Prevention Symposium (AMP), Mary Yost, MBA, president of the Sage Group, the leading research and consulting company specializing in peripheral vascular disease, presented her thoughts on the reasons why clinicians are...
At the 2023 Amputation...
09/21/2023
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement